Big Multiple Sclerosis Breakthrough - Phase 1 trial safely resets patients’ immune systems, reduces attack on myelin protein
From the article:
A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients’ immune systems’ reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research.